Skip to main content

Table 3 Blood pressure, proteinuria and use of anti hypertensive agents:

From: Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in spain: the MERENA observational cohort study

Characteristics Total
(n = 1129)
CKD Stage 3 CKD Stage 4 Pvalue
Hypertension (%) 92.7 91.2 94.1 0.06
Systolic BP < 130 mm Hg (%) 22.1 22.5 21.6 0.72
Diastolic BP < 80 mm Hg (%) 51.4 46.4 55.9 0.001
% of patients with BP < 130/80 mm Hg 17.4 19.4 16.3 0.18
% of patients with BP < 140/90 mm Hg 40.8 45.9 37.7 0.007
Systolic BP (mm Hg; mean ± SD) 141 ± 19 141 ± 19 142 ± 20 0.4
Diastolic BP (mm Hg; mean ± SD) 76 ± 11 78 ± 10 75 ± 11 0.001
Percentage of pts with proteinuria (> 300 mg/24 hrs) (%) 62.8 56.6 66.8 0.001
Proteinuria (g/24 h; mean [SD]) 1.2 ± 1.8 1.2 ± 1.8 1.3 ± 1.8 0.60
Angiotensin-converting enzyme (ACE) inhibitors (%) 43.3 46.9 40.0 0.02
Angiotensin II receptor blockers (ARB) (%) 44.8 47.7 42.2 0.06
Combined ACE and ARB (%) 10.8 12.1 9.6 0.18
Diuretics (%) 65.7 61.5 69.6 0.004
Calcium channel blockers (%) 45.7 45.8 45.6 0.94
Beta blockers (%) 21.1 22.5 19.8 0.25
Alpha blockers (%) 23.4 23.5 23.3 0.95
% of patients with 3 or more antihypertensive drugs 47.7 45.8 49.7 0.18
Mean serum potassium levels (mEq/dL; mean ± SD, [range]) 4.82 ± 0.60 [3-6.7] 4.71 ± 0.57 [3-6.4] 4.88 ± 0.61 [3.1-6.7] 0.001
% of patients with potassium levels > 5.4 mEq/dL 14.3 9.8 17.1 0.001